Why the study?
SGLT2 inhibitors provide cardiovascular protection in HF and T2DM, but evidence in CKD patients was limited and existing studies showed inconsistent results.
Do SGLT2 inhibitors reduce the risk of cardiovascular death or hospitalization for heart failure in patients with chronic kidney disease?
Comparison
SGLT2 inhibitors vs control
Design
Systematic review and meta-analysis of RCTs
Key result
SGLT2 inhibitors reduced the risk of cardiovascular death or hospitalization for heart failure by 28% compared to placebo in patients with chronic kidney disease.
Authors
Loading...
Supports SGLT2 inhibitor use in CKD to cut CV events; confirms pooled RCT benefits.
Meta-Analysis
Do SGLT2 inhibitors reduce the risk of cardiovascular death or hospitalization for heart failure in patients with chronic kidney disease?
Effect estimate: HR 0.72 (95% CI 0.66-0.78)
p-value: p=0.000
SGLT2 inhibitors significantly reduce the risk of cardiovascular death, hospitalization for heart failure, and all-cause death in patients with chronic kidney disease, without increasing serious adverse events or urinary tract infections, though they do increase reproductive tract infections.
Chen et al. (2023) conducted a meta-analysis in Chronic kidney disease. SGLT2 inhibitors vs. Placebo was evaluated on Cardiovascular death or hospitalization for heart failure (HR 0.72, 95% CI 0.66-0.78, p=0.000). SGLT2 inhibitors reduced the risk of cardiovascular death or hospitalization for heart failure by 28% compared to placebo in patients with chronic kidney disease.